Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor

Zi-Yang Shi; Ying Fang; Peng-Peng Xu; Hong-Mei Yi; Jian-Feng Li; Yan Dong; Yue Zhu; Meng-Ke Liu; Di Fu; Shuo Wang; Qing Shi; Rong Shen; Hui-Juan Zhong; Chao-Fu Wang; Shu Cheng; Li Wang; Feng Liu; Wei-Li Zhao

doi:10.1002/ctm2.1691

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (6) : e1691 DOI: 10.1002/ctm2.1691

LETTER TO THE JOURNAL

Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor

Author information +

History +

PDF

Cite this article

Download citation ▾

Zi-Yang Shi, Ying Fang, Peng-Peng Xu, Hong-Mei Yi, Jian-Feng Li, Yan Dong, Yue Zhu, Meng-Ke Liu, Di Fu, Shuo Wang, Qing Shi, Rong Shen, Hui-Juan Zhong, Chao-Fu Wang, Shu Cheng, Li Wang, Feng Liu, Wei-Li Zhao. Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor. Clinical and Translational Medicine, 2024, 14(6): e1691 DOI:10.1002/ctm2.1691

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]

Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021-4031. quiz 250.

[2]	Gu Z, Schlesner M, Hubschmann D. cola: an R/Bioconductor package for consensus partitioning through a general framework. Nucleic Acids Res. 2021;49(3):e15.

[3]	Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123(8):1214-1217.

[4]	Shen R, Fu D, Dong L, et al. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8(1):145.

[5]	Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19(12):775-790.

[6]	Fang Y, Zhang MC, Xu PP, et al. Integrative genome-wide chromatin accessibility and transcriptome profiling of diffuse large B-cell lymphoma. Clin Transl Med. 2022;12(7):e975.

[7]	Xu W, Berning P, Lenz G. Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. Blood. 2021;138(13):1110-1119.

[8]	dela Paz NG, Simeonidis S, Leo C, Rose DW, Collins T. Regulation of NF-kappaB-dependent gene expression by the POU domain transcription factor Oct-1. J Biol Chem. 2007;282(11):8424-8434.

[9]	Xu W, Liu R, Dai Y, Hong S, Dong H, Wang H. The role of p38gamma in cancer: from review to outlook. Int J Biol Sci. 2021;17(14):4036-4046.

[10]	Kalac M, Scotto L, Marchi E, et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood. 2011;118(20):5506-5516.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.